{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:39:56Z","timestamp":1792823996592,"version":"4.5.0"},"reference-count":232,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.canlet.2026.218908","type":"journal-article","created":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T14:18:34Z","timestamp":1792333114000},"page":"218908","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Tumor endothelial cells as vascular immune gatekeepers: reprogramming the vascular-immune interface for cancer immunotherapy"],"prefix":"10.1016","volume":"661","author":[{"given":"Tianming","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6251-7908","authenticated-orcid":false,"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2774-6270","authenticated-orcid":false,"given":"Jian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Sui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9228-6162","authenticated-orcid":false,"given":"Wenxue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218908_bib1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218908_bib2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm6388","article-title":"Tumors resurrect an embryonic vascular program to escape immunity","volume":"7","author":"Huijbers","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib4","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1038\/s41467-022-32738-7","article-title":"In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response","volume":"13","author":"Sahu","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218908_bib5","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41577-022-00694-4","article-title":"Immunomodulation by endothelial cells - partnering up with the immune system?","volume":"22","author":"Amersfoort","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11101511","article-title":"Tumor endothelial heterogeneity in cancer progression","volume":"11","author":"Maishi","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218908_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1749965","article-title":"Targeting MDSCs in cancer: emerging immunotherapeutic and metabolic strategies","volume":"17","author":"Dash","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218109","article-title":"Harnessing IL-2 without feeding the enemy: modern strategies to overcome regulatory T cell expansion in cancer immunotherapy","volume":"635","author":"Ma","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218908_bib9","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","article-title":"Targeting the tumour vasculature: from vessel destruction to promotion","volume":"24","author":"Guelfi","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218908_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41577-025-01211-z","article-title":"Linking tumour angiogenesis and tumour immunity","volume":"26","author":"Kabir","year":"2026","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib11","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.cell.2026.03.016","article-title":"Targeting angiogenesis: lessons from 25 years of normalizing tumor vasculature","volume":"189","author":"Subudhi","year":"2026","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218908_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002151","article-title":"VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding","volume":"9","author":"Lanitis","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218908_bib13","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41577-025-01187-w","article-title":"Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy","volume":"25","author":"Lanitis","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41571-024-00926-7","article-title":"Spatial landscapes of cancers: insights and opportunities","volume":"21","author":"Chen","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218908_bib15","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1146\/annurev-immunol-082724-123843","article-title":"Immune niches in cancer","volume":"44","author":"Slingerland","year":"2026","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib16","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41568-023-00591-5","article-title":"Understanding tumour endothelial cell heterogeneity and function from single-cell omics","volume":"23","author":"Zeng","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218908_bib17","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41580-024-00825-w","article-title":"Microenvironmental determinants of endothelial cell heterogeneity","volume":"26","author":"Gomez-Salinero","year":"2025","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218908_bib18","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41573-022-00415-5","article-title":"Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment","volume":"21","author":"Petroni","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218908_bib19","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1161\/ATVBAHA.107.158014","article-title":"VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation","volume":"28","author":"Vestweber","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.canlet.2026.218908_bib21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.molmed.2020.11.006","article-title":"Permeability of the endothelial barrier: identifying and reconciling controversies","volume":"27","author":"Claesson-Welsh","year":"2021","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib22","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006536","article-title":"Tumor endothelial cells","volume":"2","author":"Dudley","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib23","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1158\/0008-5472.CAN-04-1567","article-title":"Tumor-associated endothelial cells with cytogenetic abnormalities","volume":"64","author":"Hida","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib24","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218908_bib25","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.1073\/pnas.94.16.8761","article-title":"Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal","volume":"94","author":"Benjamin","year":"1997","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.canlet.2026.218908_bib26","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1126\/science.284.5422.1994","article-title":"Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF","volume":"284","author":"Holash","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218908_bib27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2008.12.004","article-title":"PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to Anti-VEGF treatment","volume":"15","author":"Crawford","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218908_bib28","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/S0002-9440(10)64325-8","article-title":"Distinct role of fibroblast growth Factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis","volume":"162","author":"Giavazzi","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2026.218908_bib29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13046-024-02991-3","article-title":"Tumor-derived exosomal ADAM17 promotes pre-metastatic niche formation by enhancing vascular permeability in colorectal cancer","volume":"43","author":"Li","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib30","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13046-023-02619-y","article-title":"Exosomal circTUBGCP4 promotes vascular endothelial cell tipping and colorectal cancer metastasis by activating Akt signaling pathway","volume":"42","author":"Chen","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib31","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s42003-022-03495-6","article-title":"Hypoxia-induced inhibin promotes tumor growth and vascular permeability in ovarian cancers","volume":"5","author":"Horst","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.canlet.2026.218908_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108105","article-title":"Hypoxia triggers the intravasation of clustered circulating tumor cells","volume":"32","author":"Donato","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218908_bib33","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.7150\/ijbs.78248","article-title":"IFN\u03b3 blockade in capillary leak site improves tumour chemotherapy by inhibiting lactate-induced endocytosis of vascular endothelial-cadherins","volume":"19","author":"Wang","year":"2023","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.canlet.2026.218908_bib34","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2015.00603","article-title":"T lymphocyte-endothelial interactions: emerging understanding of trafficking and antigen-specific immunity","volume":"6","author":"Carman","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib35","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1161\/ATVBAHA.120.314330","article-title":"Vascular endothelial cells and innate immunity","volume":"40","author":"Shao","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.canlet.2026.218908_bib36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood.V88.2.667.bloodjournal882667","article-title":"Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium","volume":"88","author":"Griffioen","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218908_bib37","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bbcan.2007.07.005","article-title":"Tumor blood vessels, a difficult hurdle for infiltrating leukocytes","volume":"1776","author":"Castermans","year":"2007","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2026.218908_bib38","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/039463200601900406","article-title":"Endothelial cell anergy is mediated by bFGF through the sustained activation of p38-MAPK and NF-kappaB inhibition","volume":"19","author":"Flati","year":"2006","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218908_bib39","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1096\/fj.14-250985","article-title":"VEGF suppresses T-lymphocyte infiltration in the tumor microenvironment through inhibition of NF-\u03baB-induced endothelial activation","volume":"29","author":"Huang","year":"2015","journal-title":"FASEB J."},{"key":"10.1016\/j.canlet.2026.218908_bib40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10456-022-09862-5","article-title":"Endothelial Rap1B mediates T-cell exclusion to promote tumor growth: a novel mechanism underlying vascular immunosuppression","volume":"26","author":"Sharma","year":"2023","journal-title":"Angiogenesis"},{"key":"10.1016\/j.canlet.2026.218908_bib41","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1593\/neo.09762","article-title":"Tumor-endothelium cross talk blocks recruitment of neutrophils to endothelial cells: a novel mechanism of endothelial cell anergy","volume":"11","author":"Blaheta","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2026.218908_bib42","doi-asserted-by":"crossref","first-page":"10770","DOI":"10.1158\/0008-5472.CAN-06-1609","article-title":"Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications","volume":"66","author":"Hellebrekers","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cells13100825","article-title":"The role of autophagy in vascular endothelial cell health and physiology","volume":"13","author":"Hu","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218908_bib44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41467-023-43743-9","article-title":"TET2-mediated tumor cGAS triggers endothelial STING activation to regulate vasculature remodeling and anti-tumor immunity in liver cancer","volume":"15","author":"Lv","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218908_bib45","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202318028","article-title":"Tumor endothelial cell autophagy is a key vascular-immune checkpoint in melanoma","volume":"15","author":"Verhoeven","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib46","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib47","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cytogfr.2025.12.007","article-title":"Tightly bound T-cell clusters: a new class of hyper-effector tumor killers","volume":"88","author":"Ma","year":"2026","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.canlet.2026.218908_bib48","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10456-021-09792-8","article-title":"High endothelial venules (HEVs) in immunity, inflammation and cancer","volume":"24","author":"Blanchard","year":"2021","journal-title":"Angiogenesis"},{"key":"10.1016\/j.canlet.2026.218908_bib49","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ccell.2022.01.002","article-title":"Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy","volume":"40","author":"Asrir","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218908_bib50","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1158\/0008-5472.CAN-11-0431","article-title":"Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer","volume":"71","author":"Martinet","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib51","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/s41416-019-0514-6","article-title":"High endothelial venules are associated with microsatellite instability, hereditary background and immune evasion in colorectal cancer","volume":"121","author":"Pfuderer","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218908_bib52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003353","article-title":"High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer","volume":"9","author":"Park","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218908_bib53","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.ccell.2022.11.002","article-title":"Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1(+) T lymphocyte niches through a feed-forward loop","volume":"40","author":"Hua","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218908_bib54","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1158\/0008-5472.CAN-23-2716","article-title":"LT\u03b2R agonism promotes antitumor immune responses via modulation of the tumor microenvironment","volume":"84","author":"An","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001906","article-title":"STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment","volume":"9","author":"Chelvanambi","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.canlet.2026.218908_bib56","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/s41590-025-02259-8","article-title":"Simultaneous STING and lymphotoxin-\u03b2 receptor activation induces B cell responses in tertiary lymphoid structures to potentiate antitumor immunity","volume":"26","author":"Sawada","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib57","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2093054","article-title":"Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation","volume":"11","author":"He","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218908_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2026.02.003","article-title":"Persistent spatial immune responses in glioblastoma following oncolytic virus therapy","volume":"89","author":"Ma","year":"2026","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.canlet.2026.218908_bib59","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/1541-7786.MCR-19-0897","article-title":"Tumor endothelial cell-mediated antigen-specific T-cell suppression via the PD-1\/PD-L1 pathway","volume":"18","author":"Taguchi","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib60","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","article-title":"Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218908_bib61","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/2326-6066.CIR-22-0759","article-title":"VISTA expression on cancer-associated endothelium selectively prevents T-cell extravasation","volume":"11","author":"Luk","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218908_bib62","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/bjc.2014.286","article-title":"Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells","volume":"111","author":"Kraan","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218908_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177334","article-title":"Tumor vascular normalization by B7-H3 blockade augments T lymphocyte-mediated antitumor immunity","volume":"993","author":"Dai","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218908_bib64","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.1172\/JCI129025","article-title":"Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance","volume":"129","author":"Nambiar","year":"2019","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218908_bib65","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib66","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1730538","article-title":"Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy","volume":"9","author":"Georganaki","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218908_bib67","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/cas.13560","article-title":"High IDO-1 expression in tumor endothelial cells is associated with response to immunotherapy in metastatic renal cell carcinoma","volume":"109","author":"Seeber","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2026.218908_bib68","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1593\/neo.101332","article-title":"Vascular CD39\/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate","volume":"13","author":"Feng","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.canlet.2026.218908_bib69","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2217\/imt-2018-0200","article-title":"CD73: an emerging checkpoint for cancer immunotherapy","volume":"11","author":"Chen","year":"2019","journal-title":"Immunotherapy"},{"key":"10.1016\/j.canlet.2026.218908_bib70","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/ATVBAHA.111.224162","article-title":"CD155 on human vascular endothelial cells attenuates the acquisition of effector functions in CD8 T cells","volume":"31","author":"Escalante","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.canlet.2026.218908_bib71","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1158\/2767-9764.CRC-22-0250","article-title":"Endothelial VEGFR coreceptors Neuropilin-1 and Neuropilin-2 are essential for tumor angiogenesis","volume":"2","author":"Benwell","year":"2022","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.canlet.2026.218908_bib72","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1038\/s41467-019-11280-z","article-title":"Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1","volume":"10","author":"Leclerc","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218908_bib73","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218908_bib74","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41419-025-07444-z","article-title":"Tumor vascular endothelial cells promote immune escape by upregulating PD-L1 expression via crosstalk between NF-\u03baB and STAT3 signaling pathways in nasopharyngeal carcinoma","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218908_bib75","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00262-023-03595-0","article-title":"PD-L1-positive circulating endothelial progenitor cells associated with immune response to PD-1 blockade in patients with head and neck squamous cell carcinoma","volume":"73","author":"Su","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218908_bib76","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2214350120","article-title":"Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology","volume":"120","author":"Bannoud","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218908_bib77","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.bbadis.2013.12.003","article-title":"Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis","volume":"1842","author":"Heusschen","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2026.218908_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1495907","article-title":"It's about TIME - Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma","volume":"16","author":"Knickmeier","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib79","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.TARG-13-A72","article-title":"Abstract A72: a first-in-man Phase I study of the galectin-1 (gal-1) inhibitor OTX008 given subcutaneously as a single agent to patients with advanced solid tumors","volume":"12","author":"Delord","year":"2013","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218908_bib80","series-title":"128P A Phase I Dose Escalation and Expansion Trial of LYT-200: a galectin-9 Antibody +\/- Tislelizumab, Immuno-Oncology and Technology","first-page":"20","author":"Falchook","year":"2023"},{"key":"10.1016\/j.canlet.2026.218908_bib81","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s11912-022-01265-5","article-title":"Current clinical trial landscape of OX40 agonists","volume":"24","author":"Yadav","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.canlet.2026.218908_bib82","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005301","article-title":"First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)","volume":"11","author":"Postel-Vinay","year":"2023","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.canlet.2026.218908_bib83","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.1158\/1078-0432.CCR-16-2677","article-title":"Timing of PD-1 blockade is critical to effective combination immunotherapy with Anti-OX40","volume":"23","author":"Messenheimer","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib84","doi-asserted-by":"crossref","DOI":"10.1172\/JCI186291","article-title":"Endothelial OX40 activation facilitates tumor cell escape from T cell surveillance through S1P\/YAP-mediated angiogenesis","volume":"135","author":"He","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218908_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003959","article-title":"Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy","volume":"10","author":"Anderson","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218908_bib86","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.7150\/thno.101107","article-title":"Tumor growth suppression in adoptive T cell therapy via IFN-\u03b3 targeting of tumor vascular endothelial cells","volume":"14","author":"Lin","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218908_bib87","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1200\/jco.2014.32.15_suppl.2006","article-title":"Final results of APG101_CD_002: APG101 plus reirradiation versus reirradiation in the treatment of patients with progressive glioblastoma","volume":"32","author":"Platten","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218908_bib88","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-02527-1","article-title":"Safety and tolerability of asunercept plus standard radiotherapy\/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study","volume":"11","author":"Wei","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218908_bib89","series-title":"Randomized, double-blind, placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of CAN008 plus TMZ During and After Radiation Therapy in Subjects with Newly Diagnosed Glioblastoma","author":"Multi-center","year":"2022"},{"key":"10.1016\/j.canlet.2026.218908_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217072","article-title":"CD39 transforming cancer therapy by modulating tumor microenvironment","volume":"597","author":"Xu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218908_bib91","doi-asserted-by":"crossref","DOI":"10.1177\/11786469231153111","article-title":"Endothelial Indoleamine-2,3-Dioxygenase-1 is not critically involved in regulating antitumor immunity in the central nervous system","volume":"16","author":"Abu Hejleh","year":"2023","journal-title":"Int. J. Tryptophan Res."},{"key":"10.1016\/j.canlet.2026.218908_bib92","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218908_bib93","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.187531","article-title":"Increased fatty acid delivery by tumor endothelium promotes metastatic outgrowth","volume":"10","author":"Edwards","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218908_bib94","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ccell.2016.10.006","article-title":"Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy","volume":"30","author":"Cantelmo","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218908_bib95","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12935-022-02706-8","article-title":"Recent advances and limitations of mTOR inhibitors in the treatment of cancer","volume":"22","author":"Ali","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.canlet.2026.218908_bib96","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157431","article-title":"Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models","volume":"132","author":"Zhang","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218908_bib97","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1158\/1078-0432.CCR-24-0499","article-title":"A phase Ib\/II randomized clinical trial of oleclumab with or without durvalumab plus chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma","volume":"30","author":"Coveler","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib98","doi-asserted-by":"crossref","first-page":"7018","DOI":"10.1038\/s41467-023-42744-y","article-title":"Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I\/II trial","volume":"14","author":"Buisseret","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218908_bib99","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218908_bib100","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41416-024-02796-3","article-title":"COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer","volume":"131","author":"Segal","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218908_bib101","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.3508","article-title":"ARC-9: a randomized study to evaluate etrumadenant based treatment combinations in previously treated metastatic colorectal cancer (mCRC)","volume":"42","author":"Wainberg","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218908_bib102","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218908_bib103","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/s41467-020-17811-3","article-title":"Selective inhibition of TGF-\u03b21 produced by GARP-expressing Tregs overcomes resistance to PD-1\/PD-L1 blockade in cancer","volume":"11","author":"de Streel","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218908_bib104","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41590-019-0346-9","article-title":"Adaptive plasticity of IL-10(+) and IL-35(+) T(reg) cells cooperatively promotes tumor T cell exhaustion","volume":"20","author":"Sawant","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib105","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1093\/jnci\/djm064","article-title":"Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma","volume":"99","author":"Nummer","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2026.218908_bib106","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.4049\/jimmunol.1002961","article-title":"Common lymphatic endothelial and vascular endothelial receptor-1 mediates the transmigration of regulatory T cells across human hepatic sinusoidal endothelium","volume":"186","author":"Shetty","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib107","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1158\/2326-6066.CIR-20-0784","article-title":"MHC class II antigen presentation by lymphatic endothelial cells in tumors promotes intratumoral regulatory T cell-suppressive functions","volume":"9","author":"Gkountidi","year":"2021","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218908_bib108","doi-asserted-by":"crossref","first-page":"6452","DOI":"10.1158\/1078-0432.CCR-14-1236","article-title":"Clever-1\/Stabilin-1 controls cancer growth and metastasis","volume":"20","author":"Karikoski","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib109","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136995","article-title":"Macrophage polarization States in the tumor microenvironment","author":"Boutilier","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218908_bib110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bbcan.2009.02.004","article-title":"Tumor-associated macrophages: effectors of angiogenesis and tumor progression","volume":"1796","author":"Coffelt","year":"2009","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.canlet.2026.218908_bib111","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1204506","article-title":"Macrophage-derived nitric oxide initiates T-cell diapedesis and tumor rejection","volume":"5","author":"Sektioglu","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218908_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1295257","article-title":"Tumor-associated macrophages: an effective player of the tumor microenvironment","volume":"14","author":"Basak","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib113","doi-asserted-by":"crossref","first-page":"11238","DOI":"10.1158\/0008-5472.CAN-06-1278","article-title":"Macrophages regulate the angiogenic switch in a mouse model of breast cancer","volume":"66","author":"Lin","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib114","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1158\/0008-5472.CAN-13-2421","article-title":"Myeloid WNT7b mediates the angiogenic switch and metastasis in breast cancer","volume":"74","author":"Yeo","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113067","article-title":"AXL-initiated paracrine activation of pSTAT3 enhances mesenchymal and vasculogenic supportive features of tumor-associated macrophages","volume":"42","author":"Hung","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2026.218908_bib116","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","article-title":"TREM2(+) macrophages suppress CD8(+) T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma","volume":"79","author":"Tan","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2026.218908_bib117","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1158\/0008-5472.CAN-22-0076","article-title":"Endothelial RBPJ is essential for the education of tumor-associated macrophages","volume":"82","author":"Alsina-Sanchis","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib118","article-title":"An immunosuppressive vascular niche drives macrophage polarization and immunotherapy resistance in glioblastoma","volume":"10","author":"Yang","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.canlet.2026.218908_bib119","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41467-018-03050-0","article-title":"Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2\u03b1","volume":"9","author":"Wang","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218908_bib120","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1111\/cas.70179","article-title":"Tumor endothelial cells induce M2 macrophage polarization via IL-4, enhancing tumor growth in hepatocellular carcinoma","volume":"116","author":"Matoba","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2026.218908_bib121","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14123008","article-title":"Myeloid derived suppressor cells migrate in response to flow and lymphatic endothelial cell interaction in the breast tumor microenvironment","volume":"14","author":"Roberts","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.canlet.2026.218908_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103392","article-title":"Targeting myeloid-derived suppressor cells to attenuate vasculogenic mimicry and synergistically enhance the anti-tumor effect of PD-1 inhibitor","volume":"24","author":"Li","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.canlet.2026.218908_bib123","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.chom.2025.04.022","article-title":"Microbiota-derived urocanic acid triggered by tyrosine kinase inhibitors potentiates cancer immunotherapy efficacy","volume":"33","author":"Zhang","year":"2025","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.canlet.2026.218908_bib124","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/nm1075","article-title":"Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1","volume":"10","author":"Ceradini","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib125","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2024.09.044","article-title":"CXCL12(+) tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma","volume":"82","author":"Lu","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2026.218908_bib126","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111478","article-title":"Mouse breast carcinoma monocytic\/macrophagic myeloid-derived suppressor cell infiltration as a consequence of endothelial dysfunction in shb-deficient endothelial cells increases tumor lung metastasis","volume":"22","author":"He","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218908_bib127","article-title":"TNFSF15 alleviates myeloid-derived suppressor cell-mediated cancer immunosuppression in mice","author":"Zhu","year":"2025","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.canlet.2026.218908_bib128","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00262-013-1476-9","article-title":"Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression","volume":"62","author":"Mishalian","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218908_bib129","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030536","article-title":"The good, the bad, and the ugly: neutrophils, angiogenesis, and cancer","author":"Ozel","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218908_bib130","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1158\/2159-8290.CD-15-1157","article-title":"Neutrophils suppress intraluminal NK cell-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells","volume":"6","author":"Spiegel","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2026.218908_bib131","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ccell.2017.01.007","article-title":"Endothelial Notch1 activity facilitates metastasis","volume":"31","author":"Wieland","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218908_bib132","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ijc.34134","article-title":"The oxidized-LDL\/LOX-1 axis in tumor endothelial cells enhances metastasis by recruiting neutrophils and cancer cells","volume":"151","author":"Tsumita","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218908_bib133","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1158\/2326-6066.CIR-16-0188","article-title":"CXCR2-Dependent accumulation of tumor-associated neutrophils regulates T-cell immunity in pancreatic ductal adenocarcinoma","volume":"4","author":"Chao","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218908_bib134","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1136\/gutjnl-2017-313738","article-title":"Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma","volume":"67","author":"Nywening","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2026.218908_bib135","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10169","article-title":"Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells","volume":"475","author":"Facciabene","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218908_bib136","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.molonc.2007.10.003","article-title":"Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages","volume":"1","author":"Lin","year":"2007","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.canlet.2026.218908_bib137","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ccr.2004.08.031","article-title":"Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis","volume":"6","author":"Yang","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218908_bib138","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/onc.2016.229","article-title":"Exosomes miR-126a released from MDSC induced by DOX treatment promotes lung metastasis","volume":"36","author":"Deng","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218908_bib139","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ajpath.2011.05.031","article-title":"Tumor-recruited neutrophils and neutrophil TIMP-free MMP-9 regulate coordinately the levels of tumor angiogenesis and efficiency of malignant cell intravasation","volume":"179","author":"Bekes","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2026.218908_bib140","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41590-026-02445-2","article-title":"Chemokine-defined macrophage niches establish spatial organization of tumor immunity","volume":"27","author":"Ghosh","year":"2026","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218706","article-title":"Stress-adapted cancer-associated fibroblasts as mediators of immunosuppression and therapy resistance","volume":"657","author":"Hu","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218908_bib142","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218908_bib143","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib144","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccell.2019.12.001","article-title":"An integrated gene expression landscape profiling approach to identify lung tumor endothelial cell heterogeneity and angiogenic candidates","volume":"37","author":"Goveia","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218908_bib145","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.csbj.2022.12.049","article-title":"Single-cell analysis of multiple cancer types reveals differences in endothelial cells between tumors and normal tissues","volume":"21","author":"Zhang","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.canlet.2026.218908_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218335","article-title":"Integrative single-cell and spatial transcriptomic reveals S100A16(+) tumor endothelial cells drive angiogenesis and immunosuppression in hepatocellular carcinoma","volume":"645","author":"Wang","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218908_bib147","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41698-025-00896-8","article-title":"Single-cell and spatial transcriptomics reveals the key role of MCAM(+) tip-like endothelial cells in osteosarcoma metastasis","volume":"9","author":"Tang","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2026.218908_bib148","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.immuni.2025.02.022","article-title":"Single-cell atlas of endothelial and mural cells across primary and metastatic brain tumors","volume":"58","author":"Bejarano","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218908_bib149","first-page":"387","volume":"7","author":"Ye","year":"2024"},{"key":"10.1016\/j.canlet.2026.218908_bib150","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41419-024-06598-6","article-title":"Integrating spatial and single-cell transcriptomics reveals tumor heterogeneity and intercellular networks in colorectal cancer","volume":"15","author":"Xiao","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218908_bib151","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1038\/s41467-025-58511-0","article-title":"Spatially resolved atlas of breast cancer uncovers intercellular machinery of venular niche governing lymphocyte extravasation","volume":"16","author":"Wang","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218908_bib152","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1186\/s12967-024-05750-2","article-title":"Integrative multi-omics analysis reveals the role of tumor-associated endothelial cells and their signature in prognosis of intrahepatic cholangiocarcinoma","volume":"22","author":"Jiang","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib153","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218908_bib154","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/nm988","article-title":"Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer","volume":"10","author":"Willett","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib155","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1158\/0008-5472.CAN-12-3518","article-title":"Bevacizumab-induced normalization of blood vessels in tumors hampers antibody uptake","volume":"73","author":"Arjaans","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib156","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1543526","article-title":"Beneficial effects of sunitinib on tumor microenvironment and immunotherapy targeting death receptor5","volume":"8","author":"Tsukita","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218908_bib157","doi-asserted-by":"crossref","first-page":"8990","DOI":"10.1038\/srep08990","article-title":"Angiostatic treatment prior to chemo- or photodynamic therapy improves anti-tumor efficacy","volume":"5","author":"Weiss","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218908_bib158","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12032-021-01503-z","article-title":"The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors","volume":"38","author":"Une","year":"2021","journal-title":"Med. Oncol."},{"key":"10.1016\/j.canlet.2026.218908_bib159","article-title":"Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models","volume":"7","author":"Peng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218908_bib160","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1002\/cam4.2923","article-title":"Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer-bearing mice and patients","volume":"9","author":"Liu","year":"2020","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2026.218908_bib161","doi-asserted-by":"crossref","first-page":"770","DOI":"10.15252\/emmm.201404193","article-title":"Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2","volume":"7","author":"Wu","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib162","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179860","article-title":"Pericyte phenotype switching alleviates immunosuppression and sensitizes vascularized tumors to immunotherapy in preclinical models","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218908_bib163","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s44321-025-00222-6","article-title":"Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity","volume":"17","author":"He","year":"2025","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib164","first-page":"553","article-title":"Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases","volume":"6","author":"Winkler","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218908_bib165","doi-asserted-by":"crossref","first-page":"17561","DOI":"10.1073\/pnas.1215397109","article-title":"Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy","volume":"109","author":"Huang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2026.218908_bib166","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10456-022-09863-4","article-title":"Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy","volume":"26","author":"Nowak-Sliwinska","year":"2023","journal-title":"Angiogenesis"},{"key":"10.1016\/j.canlet.2026.218908_bib167","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/S0002-9440(10)61169-8","article-title":"Down-modulation of monocyte transendothelial migration and endothelial adhesion molecule expression by fibroblast growth factor: reversal by the anti-angiogenic agent SU6668","volume":"160","author":"Zhang","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2026.218908_bib168","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1041700","article-title":"The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms","volume":"4","author":"Porcellini","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218908_bib169","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9670","article-title":"Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade","volume":"9","author":"Schmittnaegel","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib170","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0165-5728(02)00423-X","article-title":"CD40 expressed by human brain endothelial cells regulates CD4+ T cell adhesion to endothelium","volume":"134","author":"Omari","year":"2003","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.canlet.2026.218908_bib171","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-21-1047","article-title":"Neoadjuvant selicrelumab, an agonist CD40 antibody, induces changes in the tumor microenvironment in patients with resectable pancreatic cancer","volume":"27","author":"Byrne","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib172","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s00262-024-03777-4","article-title":"ALK5\/VEGFR2 dual inhibitor TU2218 alone or in combination with immune checkpoint inhibitors enhances immune-mediated antitumor effects","volume":"73","author":"Kim","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218908_bib173","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-025-02249-0","article-title":"Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218908_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218610","article-title":"Biomarker-guided strategies for tumor vasculature: from imaging advances to novel therapeutic interventions","volume":"658","author":"Purcell","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218908_bib175","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.tranon.2019.04.022","article-title":"Limitations of anti-angiogenic treatment of tumors","volume":"12","author":"Ribatti","year":"2019","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.canlet.2026.218908_bib176","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.3390\/ijms22073765","article-title":"Anti-angiogenic therapy: current challenges and future perspectives","author":"Lopes-Coelho","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218908_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103020","article-title":"Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors","volume":"84","author":"Hong","year":"2023","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218908_bib178","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ccell.2025.03.019","article-title":"CAR-T therapy in solid tumors","volume":"43","author":"Du","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218908_bib179","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138808","article-title":"CAR T cells targeting tumor endothelial marker CLEC14A inhibit tumor growth","volume":"5","author":"Zhuang","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218908_bib180","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10061273","article-title":"Binding and efficacy of Anti-Robo4 CAR-T cells against solid tumors","volume":"10","author":"Hirobe","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.canlet.2026.218908_bib181","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/2326-6066.CIR-24-0897","article-title":"Endoglin-directed CAR T cells comprehensively target tumors in advanced sarcomas","volume":"13","author":"Berger","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218908_bib182","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224015","article-title":"TEM8\/ANTXR1-specific CAR T cells mediate toxicity in vivo","volume":"14","author":"Petrovic","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218908_bib183","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","article-title":"PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial","volume":"28","author":"Narayan","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib184","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3390\/cells10051020","article-title":"In vitro evaluation of CD276-CAR NK-92 functionality, migration and invasion potential in the presence of immune inhibitory factors of the tumor microenvironment","author":"Grote","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218908_bib185","article-title":"Combinatorial immunotherapy of anti-MCAM CAR-modified expanded natural killer cells and NKTR-255 against neuroblastoma","volume":"32","author":"Luo","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.canlet.2026.218908_bib186","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1038\/s41598-020-59736-3","article-title":"Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer","volume":"10","author":"Hu","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218908_bib187","doi-asserted-by":"crossref","first-page":"9021","DOI":"10.18632\/oncotarget.24078","article-title":"VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells","volume":"9","author":"Kulemzin","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218908_bib188","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2131229","article-title":"Fully murine CD105-targeted CAR-T cells provide an immunocompetent model for CAR-T cell biology","volume":"11","author":"Lontos","year":"2022","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218908_bib189","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/0008-5472.CAN-16-1911","article-title":"TEM8\/ANTXR1-Specific CAR T cells as a targeted therapy for triple-negative breast cancer","volume":"78","author":"Byrd","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib190","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41591-024-03451-3","article-title":"Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial","volume":"31","author":"Vitanza","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib191","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s00262-024-03808-0","article-title":"Antitumor effects of intracranial injection of B7-H3-targeted Car-T and Car-Nk cells in a patient-derived glioblastoma xenograft model","volume":"73","author":"Tachi","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218908_bib192","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1186\/s12967-025-06365-x","article-title":"MUC18-Directed chimeric antigen receptor T cells for the treatment of mucosal melanoma","volume":"23","author":"Zhang","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib193","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s43018-020-00147-8","article-title":"Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma","volume":"2","author":"Ma","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2026.218908_bib194","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.cmet.2023.01.010","article-title":"PHGDH-mediated endothelial metabolism drives glioblastoma resistance to chimeric antigen receptor T cell immunotherapy","volume":"35","author":"Zhang","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.canlet.2026.218908_bib195","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","article-title":"The next frontier in immunotherapy: potential and challenges of CAR-macrophages","volume":"13","author":"Li","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218908_bib196","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70374","article-title":"Chimeric antigen receptor-macrophage therapy enters the clinic: the first-in-human trial for HER2(+) solid tumors","volume":"6","author":"Ma","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.canlet.2026.218908_bib197","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218908_bib198","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2025-7685","article-title":"CAR t-cell therapy-related cytokine release syndrome and neurotoxicity: real-world outcomes from a comprehensive cancer center","volume":"146","author":"Hsieh","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218908_bib199","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cytogfr.2025.10.001","article-title":"Reprogramming natural killer cells in the tumor microenvironment: challenges and therapeuticopportunities","volume":"86","author":"Ma","year":"2025","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.canlet.2026.218908_bib200","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s40164-022-00341-7","article-title":"Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential","volume":"11","author":"Wang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218908_bib201","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib202","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aak9679","article-title":"Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation","volume":"9","author":"Allen","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib203","article-title":"Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models","volume":"17","author":"Li","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2026.218908_bib204","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn Richard","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib205","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218908_bib206","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib207","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib208","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib209","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1198365","article-title":"Current understanding of CTLA-4: from mechanism to autoimmune diseases","volume":"14","author":"Hossen","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218908_bib210","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218908_bib211","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/2326-6066.CIR-16-0385","article-title":"Combined Anti-VEGF and Anti-CTLA-4 therapy elicits humoral immunity to Galectin-1 which is associated with favorable clinical outcomes","volume":"5","author":"Wu","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218908_bib212","first-page":"2514","article-title":"Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs","volume":"6","author":"Du Four","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib213","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.immuni.2025.02.017","article-title":"Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME","volume":"58","author":"Benmebarek","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218908_bib214","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc8922","article-title":"Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy","volume":"13","author":"Sun","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218908_bib215","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jhep.2023.10.006","article-title":"Endothelial DGKG promotes tumor angiogenesis and immune evasion in hepatocellular carcinoma","volume":"80","author":"Zhang","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2026.218908_bib216","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s43556-024-00241-8","article-title":"Cancer vaccines: platforms and current progress","volume":"6","author":"Lei","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.canlet.2026.218908_bib217","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejps.2017.12.020","article-title":"Assessment of in vivo anti-tumor activity of human umbilical vein endothelial cell vaccines prepared by various antigen forms","volume":"114","author":"Zhou","year":"2018","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.canlet.2026.218908_bib218","first-page":"3006","article-title":"Human umbilical vein endothelial cell vaccine suppresses the angiogenesis of esophageal squamous cell carcinoma in a humanized mouse model","volume":"40","author":"Liu","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.canlet.2026.218908_bib219","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1096\/fj.10-163022","article-title":"Vaccination against the extra domain-B of fibronectin as a novel tumor therapy","volume":"24","author":"Huijbers","year":"2010","journal-title":"FASEB J."},{"key":"10.1016\/j.canlet.2026.218908_bib220","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1038\/s41467-022-30063-7","article-title":"Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy","volume":"13","author":"van Beijnum","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218908_bib221","doi-asserted-by":"crossref","first-page":"8201","DOI":"10.1158\/1078-0432.CCR-05-0816","article-title":"Carbonic anhydrase II is a tumor vessel endothelium-associated antigen targeted by dendritic cell therapy","volume":"11","author":"Yoshiura","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib222","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1158\/0008-5472.CAN-06-1744","article-title":"Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity","volume":"67","author":"Ko","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218908_bib223","article-title":"Fusions of tumor-derived endothelial cells with dendritic cells induces antitumor immunity","volume":"7","author":"Huang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218908_bib224","doi-asserted-by":"crossref","DOI":"10.3390\/cells8050494","article-title":"Improved antitumor efficacy of combined vaccine based on the induced HUVECs and DC-CT26 against colorectal carcinoma","volume":"8","author":"Zhang","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218908_bib225","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1248\/bpb.b17-00145","article-title":"Cancer vaccine therapy using tumor endothelial cells as antigens suppresses solid tumor growth and metastasis","volume":"40","author":"Nomura","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.canlet.2026.218908_bib226","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.7150\/thno.53121","article-title":"Human endoglin-CD3 bispecific T cell engager antibody induces anti-tumor effect in vivo","volume":"11","author":"Zhong","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218908_bib227","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102106","article-title":"AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial","volume":"62","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.canlet.2026.218908_bib228","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106343","article-title":"A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy","volume":"182","author":"Jiao","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.canlet.2026.218908_bib229","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.853568","article-title":"The role of imaging biomarkers to guide pharmacological interventions targeting tumor hypoxia","volume":"13","author":"Gallez","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218908_bib230","doi-asserted-by":"crossref","first-page":"11964","DOI":"10.18632\/oncotarget.22600","article-title":"MR imaging biomarkers evaluating vascular normalization window after anti-vessel treatment","volume":"9","author":"Yang","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218908_bib231","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2026.218359","article-title":"Emerging biomarkers in melanoma: bridging molecular discovery and precision oncology","volume":"645","author":"Xu","year":"2026","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2026.218908_bib232","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41416-021-01330-z","article-title":"Vascular normalisation as the stepping stone into tumour microenvironment transformation","volume":"125","author":"Magnussen","year":"2021","journal-title":"Br. J. Cancer"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526006725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:27:22Z","timestamp":1792823242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526006725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":232,"alternative-id":["S0304383526006725"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218908","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor endothelial cells as vascular immune gatekeepers: reprogramming the vascular-immune interface for cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218908"}}